NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Symptomatic Paroxysmal Atrial Fibrillation- Treatment Use Study
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 入组人数
- 10
- 主要终点
- Percentage of Subjects Who Exhibited no Documented Symptomatic Paroxysmal Atrial Fibrillation (PAF) Episodes From Study Day 91 Through Day 361.
研究概览
简要总结
This trial evaluates the safety and effectiveness of catheter ablation for PAF. The investigational catheter being studied is the NAVISTAR® THERMOCOOL® irrigated-tip catheter. At the time of this study, the NAVISTAR® THERMOCOOL® Catheter was FDA-approved for commercial distribution in the U.S. for treating patients with Type I atrial flutter and drug refractory monomorphic sustained ventricular tachycardia post myocardial infarction. The catheter was approved for use in Europe for endocardial ablation for treating cardiac arrhythmias.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with symptomatic PAF who have had three (3) AF episodes in the six (6) months prior to enrollment, one of which must be documented. Documentation may include electrocardiogram (ECG), transtelephonic monitor (TTM), Holter monitor (HM), or telemetry strip.
- •Failure of at least one AAD for PAF [class I or III or AV nodal blocking agents such as beta blockers (BB) and calcium channel blockers (CCB)] as evidenced by recurrent symptomatic PAF, or intolerable side effects due to AAD.
- •Signed Patient Informed Consent Form.
- •Age 18 years or older.
- •Able and willing to comply with all pre-, post- and follow-up testing and requirements.
排除标准
- •Atrial fibrillation secondary to electrolyte imbalance, thyroid disease, or reversible or non- cardiac cause.
- •Previous ablation for atrial fibrillation.
- •Patients on amiodarone therapy at any time during the previous six (6) months.
- •AF episodes that last longer than 30 days and are terminated via cardioversion.
- •Any valvular cardiac surgical procedure.
- •CABG procedure within the last 180 days (six months).
- •Awaiting cardiac transplantation or other cardiac surgery within the next 360 days (12 months).
- •Documented left atrial thrombus on imaging (e.g. TEE).
- •History of a documented thromboembolic event within the past one (1) year.
- •Diagnosed atrial myxoma.
- •Presence of implanted ICD.
- •Significant pulmonary disease, (e.g. restrictive pulmonary disease, constrictive or chronic obstructive pulmonary disease) or any other disease or malfunction of the lungs or respiratory system that produces chronic symptoms.
- •Significant congenital anomaly or medical problem that in the opinion of the investigator would preclude enrollment in this study.
- •Women who are pregnant (by history of menstrual period or pregnancy test if the history is considered unreliable).
- •Acute illness or active systemic infection or sepsis.
- •Unstable angina.
- •Myocardial infarction within the previous 60 days (two months).
- •LVEF < 40%.
- •History of blood clotting or bleeding abnormalities.
- •Contraindication to anticoagulation (i.e. heparin or warfarin).
- •Contraindication to CT/MRA procedure.
- •Life expectancy less than 360 days (12 months).
- •Enrollment in an investigational study evaluating another device or drug.
- •Uncontrolled heart failure or NYHA class III or IV heart failure.
- •Presence of intramural thrombus, tumor or other abnormality that precludes catheter introduction or manipulation.
- •Presence of a condition that precludes vascular access.
结局指标
主要结局
Percentage of Subjects Who Exhibited no Documented Symptomatic Paroxysmal Atrial Fibrillation (PAF) Episodes From Study Day 91 Through Day 361.
时间窗: From study day 91 through day 361
A subject who exhibited no documented symptomatic PAF episodes was one who 1) had 2 or fewer repeat ablations within 90 days of the initial ablation with investigational catheter; 2) had an addition of antiarrhythmic medication which was previously ineffective for atrial fibrillation and did not exceed the previous historical maximum dosage (24 hour total dose); 3) was on atrioventricular nodal blocking agents such as beta blockers and/or calcium channel blockers and might be maintained at the current dose (ie, did not exceed previous historical maximum dosage (24 hour total dose).
The Percentage of Subjects Who Experienced Incidences of Early Onset (Within 7 Days of Ablation Procedure) Catheter-related Adverse Events.
时间窗: within 7 days of ablation procedure
Catheter-related adverse events include death, myocardial infarction, pulmonary vein stenosis, diaphragmatic paralysis, atrio-esophageal fistula, transient ischemic attack, stroke, cerebrovascular accident, thromboembolism, pericarditis, cardiac tamponade, pericardial effusion, pneumothorax, atrial perforation, vascular access complications, pulmonary edema, hospitalization (initial and prolonged), and heart block.
次要结局
- Percentage of Subjects Who Achieved Acute Success(Day 91 - 361)
- 24-hour Holter Data(1 year)
- TTM Data(1 year)
- Percentage of Subjects Who Responded to Quality of Life Assessment(1 year)